Skip to main content
Top
Published in: BMC Gastroenterology 1/2023

Open Access 01-12-2023 | Hepatic Encephalopathy | Research

A novel imaging index for predicting adverse progression in acute-on-chronic liver failure related to hepatitis B virus: the low erector spine index

Authors: Chao Zhou, Yuan Liu, Xiaoxiao Liang, Ning Zhang, Tingting He, Jingjing Zhang, Jin Zhang, Shuangnan Fu, Xin Li, Pengcheng Liu, Tianyi Zhang, Man Gong

Published in: BMC Gastroenterology | Issue 1/2023

Login to get access

Abstract

Background

It is widely known that muscle mass influences the outcomes of many chronic diseases. Erector spine mass is a convenient parameter obtained from routine abdominal computed tomography (CT). The clinical application value of erector spine mass, and whether erector spine mass could predict the outcome of disease has not been studied.

Aim

To evaluate the role of the erector spine index (ESI) calculated based on abdominal CT imaging in the progression of acute-on-chronic liver failure related to the hepatitis B virus (HBV-ACLF).

Methods

We performed a retrospective study of 118 HBV-ACLF patients and calculated the ESI (the total erector spine area normalized for height2 in meters) for each patient through abdominal CT. The findings were analyzed regarding the progression of HBV-ACLF and the ESI at baseline, including mortality and the development of complications.

Results

The ESI level was associated with mortality and the development of complications. During the 90-day follow-up period, patients with a low ESI (<12.05 cm2/m2) had higher mortality than those with a high ESI (≥ 12.05 cm2/m2) (51.7% vs. 26.7%), and the cumulative survival rates were 71.0%±4.6 and 85.8%±3.9, respectively (log-rank P = 0.003). The hazard ratios (HRs) calculated using univariable and multivariable analyses were 2.23(95% confidence interval (CI): 1.25–4.21, P = 0.005) and 2.52 (95% CI: 1.34–9.24, P = 0.011), respectively. Patients with a low ESI (<12.05 cm2/m2) had higher incidences of kidney dysfunction (43.5% vs. 23.2%, P = 0.029; log-rank P = 0.017) and hepatic encephalopathy (39.6% vs. 14.0%, P = 0.003; log-rank P = 0.010) than those with a high ESI. A low ESI was an independent risk factor for kidney dysfunction (adjusted HR = 1.36, 95% CI: 1.05–2.93, P = 0.043) and the development of hepatic encephalopathy (adjusted HR = 2.26; 95% CI: 2.05–3.13, P = 0.036). In addition, the presence of hepatic encephalopathy (the odds ratio (OR) = 2.26, 95% CI: 2.05–3.18, P = 0.006), spontaneous bacterial peritonitis (OR = 3.95, 95% CI: 1.01–5.46, P = 0.037), and kidney dysfunction (OR = 4.47, 95% CI: 1.02–9.64, P = 0.032) was independently associated with a low ESI in patients.

Conclusion

A low ESI is an independent risk factor for mortality in patients with HBV-ACLF, as well as the development of kidney dysfunction and hepatic encephalopathy.
Appendix
Available only for authorised users
Literature
1.
go back to reference Hanai T, Nishimura K, Miwa T, et al. Prevalence, association, and prognostic significance of polypharmacy and sarcopenia in patients with liver Cirrhosis. JGH Open. 2023;7(3):208–14.CrossRefPubMedPubMedCentral Hanai T, Nishimura K, Miwa T, et al. Prevalence, association, and prognostic significance of polypharmacy and sarcopenia in patients with liver Cirrhosis. JGH Open. 2023;7(3):208–14.CrossRefPubMedPubMedCentral
2.
go back to reference Tantai X, Liu Y, Yeo YH, et al. Effect of Sarcopenia on survival in patients with Cirrhosis: a meta-analysis. J Hepatol. 2022;76(3):588–99.CrossRefPubMed Tantai X, Liu Y, Yeo YH, et al. Effect of Sarcopenia on survival in patients with Cirrhosis: a meta-analysis. J Hepatol. 2022;76(3):588–99.CrossRefPubMed
3.
go back to reference Tandon P, Montano-Loza AJ, Lai JC, Dasarathy S, Merli M. Sarcopenia and frailty in decompensated Cirrhosis. J Hepatol. 2021;75:147–S162.CrossRef Tandon P, Montano-Loza AJ, Lai JC, Dasarathy S, Merli M. Sarcopenia and frailty in decompensated Cirrhosis. J Hepatol. 2021;75:147–S162.CrossRef
4.
go back to reference Hsu CS, Kao JH. Sarcopenia and chronic Liver Diseases. Expert Rev Gastroenterol Hepatol. 2018;12(12):1229–44.CrossRefPubMed Hsu CS, Kao JH. Sarcopenia and chronic Liver Diseases. Expert Rev Gastroenterol Hepatol. 2018;12(12):1229–44.CrossRefPubMed
5.
go back to reference Peng H, Zhang Q, Luo L, et al. A prognostic model of acute-on-chronic Liver Failure based on Sarcopenia. Hepatol Int. 2022;16(4):964–72.CrossRefPubMed Peng H, Zhang Q, Luo L, et al. A prognostic model of acute-on-chronic Liver Failure based on Sarcopenia. Hepatol Int. 2022;16(4):964–72.CrossRefPubMed
6.
go back to reference Bai J, Xu M, Peng F, et al. Skeletal muscle mass index as a predictor of long-term Cirrhosis onset in young non-cirrhotic males with acute-on-chronic Liver Failure. Front Nutr. 2022;9:1071373.CrossRefPubMedPubMedCentral Bai J, Xu M, Peng F, et al. Skeletal muscle mass index as a predictor of long-term Cirrhosis onset in young non-cirrhotic males with acute-on-chronic Liver Failure. Front Nutr. 2022;9:1071373.CrossRefPubMedPubMedCentral
7.
go back to reference Kumar V, Benjamin J, Shasthry V, et al. Sarcopenia in Cirrhosis: Fallout on Liver Transplantation. J Clin Exp Hepatol. 2020;10(5):467–76.CrossRefPubMed Kumar V, Benjamin J, Shasthry V, et al. Sarcopenia in Cirrhosis: Fallout on Liver Transplantation. J Clin Exp Hepatol. 2020;10(5):467–76.CrossRefPubMed
8.
go back to reference Lai JC, Tandon P, Bernal W, et al. Malnutrition, Frailty, and Sarcopenia in patients with Cirrhosis: 2021 Practice Guidance by the American Association for the study of Liver Diseases. Hepatol Baltim Md. 2021;74(3):1611–44.CrossRef Lai JC, Tandon P, Bernal W, et al. Malnutrition, Frailty, and Sarcopenia in patients with Cirrhosis: 2021 Practice Guidance by the American Association for the study of Liver Diseases. Hepatol Baltim Md. 2021;74(3):1611–44.CrossRef
9.
go back to reference Chen LK, Woo J, Assantachai P, et al. Asian Working Group for Sarcopenia: 2019 Consensus Update on Sarcopenia diagnosis and treatment. J Am Med Dir Assoc. 2020;21(3):300–307e2.CrossRefPubMed Chen LK, Woo J, Assantachai P, et al. Asian Working Group for Sarcopenia: 2019 Consensus Update on Sarcopenia diagnosis and treatment. J Am Med Dir Assoc. 2020;21(3):300–307e2.CrossRefPubMed
11.
go back to reference Ye Q, Cai JJ, Yan JQ, Lv R. Role of L3-PMI in prognostic evaluation of patients with acute-on-chronic Liver Failure related to Hepatitis B Cirrhosis. World Chin J Dig. 2021;29(20):1167–73.CrossRef Ye Q, Cai JJ, Yan JQ, Lv R. Role of L3-PMI in prognostic evaluation of patients with acute-on-chronic Liver Failure related to Hepatitis B Cirrhosis. World Chin J Dig. 2021;29(20):1167–73.CrossRef
12.
go back to reference Xu M, Li T, Kong M, et al. Psoas muscle Index can be used to Predict Long-Term Mortality in Young male patients with Acute-on-chronic Liver Failure. Front Nutr. 2022;9:811826.CrossRefPubMedPubMedCentral Xu M, Li T, Kong M, et al. Psoas muscle Index can be used to Predict Long-Term Mortality in Young male patients with Acute-on-chronic Liver Failure. Front Nutr. 2022;9:811826.CrossRefPubMedPubMedCentral
13.
go back to reference Meyer F, Bannert K, Wiese M, et al. Molecular mechanism contributing to Malnutrition and Sarcopenia in patients with liver Cirrhosis. Int J Mol Sci. 2020;21(15):5357.CrossRefPubMedPubMedCentral Meyer F, Bannert K, Wiese M, et al. Molecular mechanism contributing to Malnutrition and Sarcopenia in patients with liver Cirrhosis. Int J Mol Sci. 2020;21(15):5357.CrossRefPubMedPubMedCentral
14.
go back to reference Zhou C, Zhang N, He TT, et al. High levels of serum interleukin-6 increase mortality of Hepatitis B virus-associated acute-on-chronic Liver Failure. World J Gastroenterol. 2020;26(30):4479–88.CrossRefPubMedPubMedCentral Zhou C, Zhang N, He TT, et al. High levels of serum interleukin-6 increase mortality of Hepatitis B virus-associated acute-on-chronic Liver Failure. World J Gastroenterol. 2020;26(30):4479–88.CrossRefPubMedPubMedCentral
15.
go back to reference APASL ACLF Research Consortium (AARC) for APASL ACLF working Party, Sarin SK, Choudhury A, et al. Acute-on-chronic Liver Failure: consensus recommendations of the Asian Pacific association for the study of the liver (APASL): an update. Hepatol Int. 2019;13(4):353–90.CrossRef APASL ACLF Research Consortium (AARC) for APASL ACLF working Party, Sarin SK, Choudhury A, et al. Acute-on-chronic Liver Failure: consensus recommendations of the Asian Pacific association for the study of the liver (APASL): an update. Hepatol Int. 2019;13(4):353–90.CrossRef
16.
go back to reference Moreau R, Jalan R, Gines P, et al. Acute-on-chronic Liver Failure is a distinct syndrome that develops in patients with acute decompensation of Cirrhosis. Gastroenterology. 2013;144(7):1426–37. 1437.e1-9.CrossRefPubMed Moreau R, Jalan R, Gines P, et al. Acute-on-chronic Liver Failure is a distinct syndrome that develops in patients with acute decompensation of Cirrhosis. Gastroenterology. 2013;144(7):1426–37. 1437.e1-9.CrossRefPubMed
17.
go back to reference Chinese Society of Hepatology, Chinese Medical Association, Xu X, Duan Z, et al. Chinese guidelines on the management of Ascites and its related Complications in Cirrhosis. Hepatol Int. 2019;13(1):1–21.CrossRef Chinese Society of Hepatology, Chinese Medical Association, Xu X, Duan Z, et al. Chinese guidelines on the management of Ascites and its related Complications in Cirrhosis. Hepatol Int. 2019;13(1):1–21.CrossRef
18.
go back to reference Mitsiopoulos N, Baumgartner RN, Heymsfield SB, Lyons W, Gallagher D, Ross R. Cadaver validation of skeletal muscle measurement by magnetic resonance imaging and computerized tomography. J Appl Physiol. 1998;85(1):115–22.CrossRefPubMed Mitsiopoulos N, Baumgartner RN, Heymsfield SB, Lyons W, Gallagher D, Ross R. Cadaver validation of skeletal muscle measurement by magnetic resonance imaging and computerized tomography. J Appl Physiol. 1998;85(1):115–22.CrossRefPubMed
19.
go back to reference Liu J, Ma J, Yang C, et al. Sarcopenia in patients with Cirrhosis after Transjugular Intrahepatic Portosystemic Shunt Placement. Radiology. 2022;303(3):711–9.CrossRefPubMed Liu J, Ma J, Yang C, et al. Sarcopenia in patients with Cirrhosis after Transjugular Intrahepatic Portosystemic Shunt Placement. Radiology. 2022;303(3):711–9.CrossRefPubMed
21.
go back to reference Hanai T, Shiraki M, Watanabe S, et al. Sarcopenia predicts minimal hepatic encephalopathy in patients with liver Cirrhosis: Sarcopenia predicts MHE in cirrhotic patients. Hepatol Res. 2017;47(13):1359–67.CrossRefPubMed Hanai T, Shiraki M, Watanabe S, et al. Sarcopenia predicts minimal hepatic encephalopathy in patients with liver Cirrhosis: Sarcopenia predicts MHE in cirrhotic patients. Hepatol Res. 2017;47(13):1359–67.CrossRefPubMed
22.
go back to reference Lattanzi B, Nardelli S, Pigliacelli A, et al. The additive value of Sarcopenia, myosteatosis and hepatic encephalopathy in the predictivity of model for end-stage Liver Disease. Dig Liver Dis. 2019;51(11):1508–12.CrossRefPubMed Lattanzi B, Nardelli S, Pigliacelli A, et al. The additive value of Sarcopenia, myosteatosis and hepatic encephalopathy in the predictivity of model for end-stage Liver Disease. Dig Liver Dis. 2019;51(11):1508–12.CrossRefPubMed
23.
go back to reference Hiraoka A, Kumada T, Kariyama K, et al. Clinical importance of muscle volume in lenvatinib treatment for hepatocellular carcinoma: analysis adjusted with inverse probability weighting. J Gastroenterol Hepatol. 2021;36(7):1812–9.CrossRefPubMed Hiraoka A, Kumada T, Kariyama K, et al. Clinical importance of muscle volume in lenvatinib treatment for hepatocellular carcinoma: analysis adjusted with inverse probability weighting. J Gastroenterol Hepatol. 2021;36(7):1812–9.CrossRefPubMed
24.
go back to reference Lee Yho, Kim SU, Song K, et al. Sarcopenia is associated with significant liver fibrosis independently of obesity and insulin resistance in nonalcoholic fatty Liver Disease. Hepatology. 2016;63(3):776–86.CrossRefPubMed Lee Yho, Kim SU, Song K, et al. Sarcopenia is associated with significant liver fibrosis independently of obesity and insulin resistance in nonalcoholic fatty Liver Disease. Hepatology. 2016;63(3):776–86.CrossRefPubMed
25.
go back to reference Kalafateli M, Mantzoukis K, Choi Yau Y, et al. Malnutrition and sarcopenia predict post-liver transplantation outcomes independently of the model for end-stage Liver Disease score: Malnutrition and post-liver transplant morbidity. J Cachexia Sarcopenia Muscle. 2017;8(1):113–21.CrossRefPubMed Kalafateli M, Mantzoukis K, Choi Yau Y, et al. Malnutrition and sarcopenia predict post-liver transplantation outcomes independently of the model for end-stage Liver Disease score: Malnutrition and post-liver transplant morbidity. J Cachexia Sarcopenia Muscle. 2017;8(1):113–21.CrossRefPubMed
26.
go back to reference Mauro E, Crespo G, Martinez-Garmendia A, et al. Cystatin C and Sarcopenia Predict Acute on chronic Liver Failure development and mortality in patients on the liver transplant waiting list. Transplantation. 2020;104(7):e188–98.CrossRefPubMed Mauro E, Crespo G, Martinez-Garmendia A, et al. Cystatin C and Sarcopenia Predict Acute on chronic Liver Failure development and mortality in patients on the liver transplant waiting list. Transplantation. 2020;104(7):e188–98.CrossRefPubMed
27.
go back to reference Montano-Loza AJ, Meza-Junco J, Baracos VE, et al. Severe muscle depletion predicts postoperative length of stay but is not associated with survival after liver transplantation. Liver Transpl. 2014;20(6):640–8.CrossRefPubMed Montano-Loza AJ, Meza-Junco J, Baracos VE, et al. Severe muscle depletion predicts postoperative length of stay but is not associated with survival after liver transplantation. Liver Transpl. 2014;20(6):640–8.CrossRefPubMed
28.
go back to reference Nardelli S, Lattanzi B, Merli M, et al. Muscle alterations are Associated with minimal and overt hepatic encephalopathy in patients with liver Cirrhosis. Hepatology. 2019;70(5):1704–13.CrossRefPubMed Nardelli S, Lattanzi B, Merli M, et al. Muscle alterations are Associated with minimal and overt hepatic encephalopathy in patients with liver Cirrhosis. Hepatology. 2019;70(5):1704–13.CrossRefPubMed
29.
go back to reference Bhanji RA, Moctezuma-Velazquez C, Duarte-Rojo A, et al. Myosteatosis and sarcopenia are associated with hepatic encephalopathy in patients with Cirrhosis. Hepatol Int. 2018;12(4):377–86.CrossRefPubMed Bhanji RA, Moctezuma-Velazquez C, Duarte-Rojo A, et al. Myosteatosis and sarcopenia are associated with hepatic encephalopathy in patients with Cirrhosis. Hepatol Int. 2018;12(4):377–86.CrossRefPubMed
30.
31.
32.
go back to reference Kumar A, Davuluri G, Silva RN. Ammonia lowering reverses Sarcopenia of Cirrhosis by restoring skeletal muscle proteostasis: Kumar et al. Hepatology. 2017;65(6):2045–58.CrossRefPubMed Kumar A, Davuluri G, Silva RN. Ammonia lowering reverses Sarcopenia of Cirrhosis by restoring skeletal muscle proteostasis: Kumar et al. Hepatology. 2017;65(6):2045–58.CrossRefPubMed
33.
go back to reference Dasarathy S. Cause and management of muscle wasting in chronic Liver Disease. Curr Opin Gastroenterol. 2016;32(3):159–65.PubMedPubMedCentral Dasarathy S. Cause and management of muscle wasting in chronic Liver Disease. Curr Opin Gastroenterol. 2016;32(3):159–65.PubMedPubMedCentral
Metadata
Title
A novel imaging index for predicting adverse progression in acute-on-chronic liver failure related to hepatitis B virus: the low erector spine index
Authors
Chao Zhou
Yuan Liu
Xiaoxiao Liang
Ning Zhang
Tingting He
Jingjing Zhang
Jin Zhang
Shuangnan Fu
Xin Li
Pengcheng Liu
Tianyi Zhang
Man Gong
Publication date
01-12-2023
Publisher
BioMed Central
Published in
BMC Gastroenterology / Issue 1/2023
Electronic ISSN: 1471-230X
DOI
https://doi.org/10.1186/s12876-023-02995-x

Other articles of this Issue 1/2023

BMC Gastroenterology 1/2023 Go to the issue
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.